Education/ACR/EULAR

It was a beautiful Year in Preview from @AlexisOgdie - here's a summary of her take on what might be to come in rheumatology in the year ahead #ACR26 @RheumNow https://t.co/DneNoUkc7u https://t.co/jlAdwZYAQI

ACR 2026 Rheumatology Round Up https://t.co/ZpvYJRZvn0

Dr. John Cush

ACR 2026 Day 3 Report https://t.co/7DbbFhEtp4 https://t.co/tCB9tKgTup

ACR 2026 Day 3 Report | RheumNow

Article

Why I Go to ACR Convergence Every Year (11.13.2026)

Jack Cush, MD Nov 13, 2026

Dr. Cush reviews best reasons to go to ACR annually, but also the best way to learn ACR26 content this year.

All RA-ILD deserves a trial of immunomodulation The optimum treatment approach in RA-ILD remains an area mired in controversy. This is evident from the contrasting views taken by the 2 recent expert guidelines from ACR and EULAR, which advocate for very different treatment https://t.co/vxr8NDruGI

ACR 2026 – Day 2 Report https://t.co/H5aJMSwHwk https://t.co/gzGSaA9czB

ACR 2026 – Day 2 Report | RheumNow

Article

To Pulse or Not to Pulse in ANCA Associated Vasculitis?

Michael Putman, MD, MSCI Nov 12, 2026

Randomized trials typically get top billing at ACR Convergence, but the past three years have seen “target trial emulations” land coveted plenary sessions and oral abstracts. These are not actually trials; instead, they are a new-ish approach to generating causal inferences from observational

Is 60-40-20 broken? RA trial rule of thumb: roughly 60%-40%-20% for ACR20-50-70 girocitinib (JAK1/Tyk2) vs tofacitinib ACR20: 91% vs 75% ACR50: 73% vs 49% ACR70: 44% vs 25% there will be debate (all in China, tofa exposure) but what a meeting for H2H ABSTLB21 #ACR26 @RheumNow https://t.co/SmOCzqqxFg

https://x.com/drdavidliew/status/2120645121083633898/photo/1

Final #ACR2026 post (maybe? 😄)! Huge shoutout to @RheumNow and the incredible team for their phenomenal work in rheumatology education! Can’t believe it took me this long to collaborate with them, but I have a feeling this is the beginning of a long-term relationship! 🙌

@RheumNow The narrative medicine interactive session at #ACR2026 was well attended and had a lot of interesting exchange of thoughts and ideas. Holistic care of patients, attention to caregiver burnout and ensuring provider well being is the need of the hour in rheumatology.

@RheumNow 🎉 Celebrated 50 years of #PediatricRheumatology at #ACR2026! Meet the Masters: 3 pioneers reflected on the evolution of our field—from early genetics and DMARDs to biologics—and envisioned the future of precision medicine, novel therapies, and mentorship. What a treat

@RheumNow #1! 🌍 Global pediatric rheumatology workforce challenges! A survey across 32 countries found 40% lacked in-country training programs. Variable accreditation, limited funding & poor specialty awareness remain key barriers. Abstract 1483. #ACR2026

ACR26 summary, AI and documentation: errors on all five AI platforms tested against guidelines, and cDAPSA documented in 4.9% of PsA records @rheumnow #ACR26 Abstract#0869 Abstract#1348

@RheumNow #2. Abstract 1876. A consensus-driven core outcome set for healthcare transition in adolescents and young adults with JIA identifies 10 outcomes spanning the Quadruple Aim framework: Population health, experience of care, cost of care, provider experience. #ACR2026

#ACR26 #2965: AI-generated answers to common pt Qs were rated similarly to rheumatologist-written answers. The highest-value approach, was AI plus rheumatologist review, which improved utility, readability, and completeness. The future may be hybrid, not human versus AI.@RheumNow

ACR26 summary, diagnosis and classification: lower sensitivity of the 2025 ASAS SPARTAN criteria in early axSpA, and a 28 month reduction in diagnostic delay with an integrated referral pathway. @rheumnow #ACR26 Abstract#2347 Abstract#2540

@RheumNow #4. Continuing the conversation on unmet needs in cSLE. Abstract 2486. The PLUMM trial highlights barriers to clinical trial enrollment in pediatrics. Strict eligibility criteria, patient preference, logistic and feasibility issues limit participation. #ACR2026

The 2026 ACR, SAA and SPARTAN guidelines for the management of axial spondyloarthritis. Watch the @RheumNow Daily Recap Day 2 to hear the discussion about it #ACR26 #axSpA https://t.co/RVX7V8ll6d

Abstract 2969: surveyed pts w/ lupus about clinical trial awareness - 87% patients reported informed about their dx w/ physicians as main source (94%) - cliniical trial knowledge lower (44%) - 84% expressed interest in trials - travel most common barrier @RheumNow #ACR26

RheumNow’s expanded #ACR26 coverage is sponsored by UCB. All coverage content is independently selected by RheumNow and its faculty.

RheumNow’s expanded coverage of the #ACR26 annual meeting is sponsored by Eli Lilly and Company. All coverage content is independently selected by RheumNow and its faculty.

ACR 2026 RheumNow Day 4 Recap https://t.co/FpWPBred0v

Dr. John Cush

Article

Two Prescriptions, One Patient

Antoni Chan, MD, PhD Nov 11, 2026

Obesity, in particular in psoriatic arthritis (PsA) was widely covered at #ACR26. This is from the recognition of the size of the problem.

Article

ACR 2026 Day 4 Report

Jack Cush, MD Nov 11, 2026

The last day of ACR 2026 was a half-day but a busy day, with several exciting reports, especially coming from the late-breaking abstracts.

RheumNow’s expanded coverage of #ACR26 annual meeting is sponsored by Beeline Medicines, Boehringer Ingelheim, Bristol Myers Squibb, and Tonix. All coverage content is independently selected by RheumNow and its faculty.

Therapeutic Updates

The Four Pillars of Weight Loss

RheumNow

Sep 08, 2026

Watch our 'Four Pillars of Weight Loss' 8-part series as part of this month's The Obesity Imperative campaign.

Read Post

ACR 2026 Daily Podcasts - Day3b
Nov 11, 2026
ACR 2026 RheumNow Day 1 Recap
Nov 09, 2026
Obesity & Inflammation: Understanding the Impact on Rheumatic Disease
Sep 16, 2026